Imagen de Portada

TP53 disruptive mutation predicts platinum‐based chemotherapy and PD‐1/PD‐L1 blockade response in urothelial carcinoma

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Kaifeng Jin, Jingtong Xu, Xiaohe Su, Ziyue Xu, Bingyu Li, Ge Liu, Hailong Liu, Yiwei Wang, Yu Zhu, Le Xu, Weijuan Zhang, Zhaopei Liu, Zewei Wang, Yuan Chang, Jiejie Xu
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	The Journal of Pathology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
por: Ge Liu, et al.
Publicado: (2024)

Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma
por: Lingkai Zhang, et al.
Publicado: (2025)

TP53 mutations in urothelial carcinoma: not all one and the same†
por: Alexis R Barr, et al.
Publicado: (2024)

PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance
por: Tong Wang, et al.
Publicado: (2024)

PD ‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR / MSS colorectal cancer
por: Fengyun Pei, et al.
Publicado: (2024)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
por: Lingfeng Diao, et al.
Publicado: (2024)

Immunohistochemistry‐based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy
por: Csilla Olah, et al.
Publicado: (2025)

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade
por: Shaoyong Peng, et al.
Publicado: (2025)

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer
por: Yifan Cao, et al.
Publicado: (2024)

Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy
por: Yi Zhu, et al.
Publicado: (2026)

Insulin‐Like Growth Factor 1 Receptor Expression for Predicting PD‑1/PD‑L1 Inhibitor Response in Hypopharyngeal Squamous Cell Carcinoma
por: Wen‐Jing Li, et al.
Publicado: (2025)

Sex‐based immune microenvironmental feature heterogeneity in response to PD ‐1 blockade in combination with chemotherapy for patients with untreated advanced non‐small‐cell lung cancer
por: Xiaofeng Yu, et al.
Publicado: (2024)

Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
por: Li Li, et al.
Publicado: (2024)

Role of PD‐L1 in Arthritis: Comment on the Article by Wood et al
por: Wang‐Dong Xu, et al.
Publicado: (2024)

GHITM regulates malignant phenotype and sensitivity to PD‐1 blockade of renal cancer cells via Notch signalling
por: Shiyu Huang, et al.
Publicado: (2024)

HHLA2 is more significantly associated with poor prognosis in TSCC than PD‐L1
por: Yi Li, et al.
Publicado: (2024)

Biomarker‐based long‐term safety and efficacy of PD ‐1/ PD ‐ L1 inhibitors combined with chemotherapy in advanced gastroesophageal carcinomas: A systematic review and meta‐analysis
por: Muhammad Ahsan, et al.
Publicado: (2026)

824 | R‐CHOP WITH SINTILIZUMAB IN FIRST‐LINE TREATMENT OF LARGE B‐CELL LYMPHOMA PATIENTS WITH TP53 MUTATIONS AND PD‐L1 EXPRESSION: A RANDOMIZED, MULTICENTER CLINICAL STUDY
por: Y. Che, et al.
Publicado: (2025)

The IARC TP53 mutation database: a resource for studying the significance of TP53 mutations in human cancers
por: AUDREY PETITJEAN
Publicado: (2007)

An artificial intelligence‐powered PD‐L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability
por: Kyu Sang Lee, et al.
Publicado: (2024)

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma
por: Konrad Stawiski, et al.
Publicado: (2026)

AML cell‐derived exosomes suppress the activation and cytotoxicity of NK cells in AML via PD‐1/PD‐L1 pathway
por: Dandan Wang, et al.
Publicado: (2024)

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
por: Xintong Li, et al.
Publicado: (2024)

The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer
por: Hao Hu, et al.
Publicado: (2024)

Sezary syndrome revealed by PD‐L1 blockade for tumor stage mycosis fungoides
por: Jérémie Delaleu, et al.
Publicado: (2024)

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
por: Thomas M. Kuczmarski, et al.
Publicado: (2025)

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011
por: Peter H. O’Donnell, et al.
Publicado: (2024)

ChatPD: An LLM-driven Paper-Dataset Networking System
por: Xu, Anjie, et al.
Publicado: (2025)

Targeting PD‐L1 for Ischemic Stroke Recovery: Age‐Dependent Modulation of Immune and BBB Pathways
por: Hang Hang, et al.
Publicado: (2025)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies
por: Yan Sun, et al.
Publicado: (2025)

PDDM: Pseudo Depth Diffusion Model for RGB-PD Semantic Segmentation Based in Complex Indoor Scenes
por: Xu, Xinhua, et al.
Publicado: (2025)

Immune Modulatory Effects of PD ‐1/ PD ‐ L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis
por: Jianing Li, et al.
Publicado: (2025)

Icaritin Sensitizes Hepatocellular Carcinoma to PD ‐ L1 Therapy by NQO1 ‐Dependent Ferroptosis Induction
por: Zhen Li, et al.
Publicado: (2026)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
por: Qichen Zhang, et al.
Publicado: (2025)

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies
por: Chi Zhang, et al.
Publicado: (2025)

Cordycepin Targets HRD1 to Promote Cancer Cell PD‐L1 Ubiquitin–Proteasome Degradation and Increase Antitumor Immunity
por: Xiangxin Geng, et al.
Publicado: (2025)

TP53 and Beta-catenin mutations in liver tumours
por: PIERRE HAINAUT
Publicado: (2007)

Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT‐PD‐L1 Axis
por: Ning Wang, et al.
Publicado: (2024)

TP53 mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV‐2 study
por: Eliana Bignotti, et al.
Publicado: (2024)

Inhibition of the Rho / MRTF pathway improves the response of BRAF ‐resistant melanoma to PD1 / PDL1 blockade
por: Bardees M. Foda, et al.
Publicado: (2024)